These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 26731207)
41. Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage. Chuang LH; Wang NK; Chen YP; Yeung L; Hwang YS; Chen KJ; Wu WC; Chen TL; Lai CC Retina; 2013 Apr; 33(4):798-802. PubMed ID: 23114407 [TBL] [Abstract][Full Text] [Related]
42. Effect of retinal laser photocoagulation on the activity of metalloproteinases and the alpha(2)-macroglobulin proteolytic state in the vitreous of eyes with proliferative diabetic retinopathy. Sánchez MC; Luna JD; Barcelona PF; Gramajo AL; Juarez PC; Riera CM; Chiabrando GA Exp Eye Res; 2007 Nov; 85(5):644-50. PubMed ID: 17826767 [TBL] [Abstract][Full Text] [Related]
43. Visual prognosis after panretinal photocoagulation for proliferative diabetic retinopathy. Bek T; Erlandsen M Acta Ophthalmol Scand; 2006 Feb; 84(1):16-20. PubMed ID: 16445434 [TBL] [Abstract][Full Text] [Related]
44. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Lee BJ; Yu HG Retina; 2010; 30(10):1671-7. PubMed ID: 21060273 [TBL] [Abstract][Full Text] [Related]
45. Vitrectomy and endolaser for complications of proliferative diabetic retinopathy. Ramsay RC; Cantrill HL; Knobloch WH Can J Ophthalmol; 1986 Aug; 21(5):170-4. PubMed ID: 2428455 [TBL] [Abstract][Full Text] [Related]
46. Multiple factors in the prediction of risk of recurrent vitreous haemorrhage after sutureless vitrectomy for non-clearing vitreous haemorrhage in patients with diabetic retinopathy. Ding Y; Yao B; Hang H; Ye H BMC Ophthalmol; 2020 Jul; 20(1):292. PubMed ID: 32677996 [TBL] [Abstract][Full Text] [Related]
47. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344 [TBL] [Abstract][Full Text] [Related]
48. A pilot study of viscoelastic agent to prevent recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy. Qiu CY; Shi YY; Zhao HW; Gong YB; Nie C; Wang MG; Jia R; Zhao J; Wang X; Luo L BMC Ophthalmol; 2022 Dec; 22(1):509. PubMed ID: 36550421 [TBL] [Abstract][Full Text] [Related]
49. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Romano MR; Gibran SK; Marticorena J; Wong D; Heimann H Eye (Lond); 2009 Aug; 23(8):1698-701. PubMed ID: 19039332 [TBL] [Abstract][Full Text] [Related]
50. Early vitrectomy for dense vitreous hemorrhage in adults with non-traumatic and non-diabetic retinopathy. Zhang T; Zhang J; Sun X; Tian J; Shi W; Yuan G J Int Med Res; 2017 Dec; 45(6):2065-2071. PubMed ID: 28627981 [TBL] [Abstract][Full Text] [Related]
51. Anterior retinal cryotherapy and intravitreal injection of bevacizumab in the treatment of nonclearing vitreous hemorrhage in proliferative diabetic retinopathy. Hsieh MC; Yeh PT; Yang CM; Yang CH J Ocul Pharmacol Ther; 2014 May; 30(4):353-8. PubMed ID: 24359129 [TBL] [Abstract][Full Text] [Related]
52. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Mason JO; Colagross CT; Haleman T; Fuller JJ; White MF; Feist RM; Emond TL; McGwin G Am J Ophthalmol; 2005 Aug; 140(2):231-5. PubMed ID: 15992755 [TBL] [Abstract][Full Text] [Related]